This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.
Introduction
Venous thromboembolism (VTE) often occurs in patients with advanced lung cancer (1) . Registry data have shown a 3-fold reduction in the 1-year survival of patients with cancer and VTE in comparison to those without VTE (2) . The risk of VTE recurrence in patients with VTE and cancer is more than 3-fold higher than that in patients without cancer (3). Thus, both the initial treatment and prophylaxis against VTE recurrence are important for patients with cancer and VTE. Low-molecular weight heparin (LMWH) is recommended for the initial 5 to 10 days of treatment for VTE and also as long-term prophylactic therapy for at least 6 months (4). LMWH is preferred over unfractionated heparin (UFH) because the mortality rate and the incidence of thrombosis and bleeding in patients who receive LMWH is reduced in comparison to patients who receive UFH. However, UFH is widely used for patients with VTE and cancer because the administration of LMWH for VTE in nonsurgical patients is not covered by health insurance in Japan. For long-term prophylactic therapy, vitamin K antagonists (VKAs) are acceptable if heparin is not available. Since LMWH and UFH must be administered via intermittent subcutaneous injection or continuous intravenous injection, and thus impair the quality of life (QOL) of the patient, VKAs are widely used for long-term prophylactic therapy in Japan.
The use of novel oral anticoagulants (NOACs), also known as direct oral anticoagulants, is not currently recommended for cancer patients with VTE due to the limited available data (4, 5) . However, NOACs have been widely used as anticoagulants for patients without cancer (6) , and recent studies have reported the efficacy and safety of NOACs in patients with VTE (7, 8) .
We herein report the successful application of edoxaban, an NOAC, in the treatment of the recurrence of VTE in a patient with non-small cell lung cancer after tumor shrinkage was achieved using chemotherapy. This is the first re- Days a er the rst visit to the previous doctor 
Case Report
The patient was a 66-year-old man who had previously presented (at another hospital) with breathlessness and bilateral pedal edema. Computed tomography (CT) revealed a nodule in the left upper lobe that was suggestive of lung cancer and which was also associated with pulmonary embolism (PE) and deep venous thrombosis (DVT). His Ddimer level was high (14.6 μg/mL). The patient was not obese and was not a current smoker. There were no congenital factors associated with thrombosis in his family history. His anti-β2glycoprotein I antibody level was within the normal level. Thus, we concluded that it was likely that his VTE had been caused by lung cancer. VTE was considered to be a greater threat than lung cancer; thus, treatment for VTE was administered before the diagnosis of lung cancer. The schedule of treatment for VTE and lung cancer is shown in Fig. 1 . The patient was hospitalized and was initially treated with a continuous intravenous injection of heparin sodium, which is a UFH. The symptoms improved and the D-dimer level decreased to 5.4 μg/mL. Seven days after the first visit, heparin sodium was switched to oral warfarin for long-term prophylactic therapy. The patient was discharged on a VKA (warfarin, 4 mg, daily). The International Normalized Ratio of Prothrombin Time (PT-INR) was maintained within the appropriate range (INR 2.0-3.4) for approximately 3 weeks. On the 34th day after his first visit to the previous doctor, the patient was referred to our department. At that time, his breathlessness had become worse and the D-dimer level had increased to 11.2 μg/mL. CT revealed that the PE and DVT had progressed (Fig. 2) . Thus, the patient was hospitalized again and was treated with a continuous intravenous injection of heparin sodium. Two days later, the D-dimer level decreased to 2.8 μg/mL and his breathlessness and pedal edema disappeared. Heparin sodium was switched to oral edoxaban (60 mg, daily) as longterm prophylactic therapy. However, the D-dimer level increased to 7.0 μg/mL after one week. Thus, treatment failure was suspected (9) . We discontinued treatment with edoxaban and started the intermittent subcutaneous injection of heparin calcium, a UFH. During heparin treatment, the D-dimer level decreased and CT showed that the PE and DVT were reduced in size.
The patient was diagnosed with primary lung adenocarcinoma (cT1aN3M0 stage IIIB) based on the findings of a bronchoscopic biopsy of the enlarged mediastinal lymph nodes. From the 54th day, he was treated with chemotherapy consisting of carboplatin (area under the concentrationtime curve 6, once every 3 weeks) and nab-paclitaxel (100 mg/m 2 , weekly) along with heparin calcium. After the second course of chemotherapy, contrast CT on the 118th day showed tumor shrinkage and the regression of VTE; the DVT had disappeared, and only a small thrombus remained in left arteria segmentalis basalis anterior (A8) (Fig. 2) . The patient had no symptoms of VTE; however, he complained of skin irritation caused by the intermittent subcutaneous injection of heparin calcium. After the third course of chemo- 
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therapy and from the 150th day, treatment with edoxaban was reattempted. After the second switch from the heparin injection to edoxaban, the D-dimer level remained within the normal range, and a very small thrombus remained in the left pulmonary artery, as observed on contrast CT. The sixth course of chemotherapy was completed on the 209th day. The CT findings revealed a partial response and that a small thrombus remained. Neither the symptoms nor the Ddimer level became worse. The patient continued to receive edoxaban without any adverse events and the skin irritation from the injection of heparin ceased. Thus, the second application of edoxaban was successful. Informed consent was obtained from the patient for the publication of this case report and any accompanying images, laboratory data, and pathological data.
Discussion
The patient in the present case suffered from VTE associated with lung cancer. UFH was initially used to control the VTE. Attempts to switch anti-coagulants to warfarin (VKA) or edoxaban (NOAC) failed. Chemotherapy was then administered to control the tumor, which was considered to be the most likely cause of VTE. After the shrinkage of the tumor through chemotherapy, we were able to switch anticoagulation therapy from UFH to edoxaban. The relief of the skin irritation caused by the subcutaneous injection of UFH improved the patient's QOL. To the best of our knowledge, this is the first report to indicate that tumor size and activity plays an important role in the efficacy of anticoagulation therapy. The present case suggests that NOACs can be used as maintenance therapy for VTE when the tumor size and activity are controlled.
In the guidelines of both the American Society of Clinical Oncology and the European Society for Medical Oncology, NOACs are not currently recommended for patients with both cancer and VTE because of limited data (4, 5) . NOACs were recently reported to show good efficacy in a population of patients with VTE that included some cancer patients. Edoxaban was not inferior -in terms of efficacy -to warfarin as long-term prophylactic therapy after initial treatment with heparin, and was associated with a significantly lower risk of bleeding in patients with VTE; 9.2% of these patients were suffering from cancer (7). Rivaroxaban, an NOAC, had similar efficacy to the combination of LMWH and warfarin or acenocoumarol in patients with VTE; 6.8% of these patients were suffering from active cancer (8) . NOACs are a convenient treatment and allow for a good QOL for several reasons: they are orally administered and have a wide therapeutic window, any drug and food interac-tions are minor, and there is no need for strict laboratory monitoring (10) . Based on these previous reports, we chose NOAC as an alternative to UFH, rather than VKA. Edoxaban was selected because -at that time -it was the only NOAC that was covered by health insurance for the treatment of VTE in Japan.
Thrombosis is a common complication of cancer and anticancer chemotherapy. Substances derived from tumor cells, such as tissue factor (TF), plasminogen activator inhibitor, mucin, cytokines and other procoagulants, activate various mechanisms of thrombi formation (11, 12) . Warfarin inhibits the vitamin K-dependent synthesis of clotting factors II, VII, IX, and X (13). NOACs directly inhibit the final steps of the coagulation cascade, which are clotting factor Xa (inhibited by edoxaban, rivaroxaban, and apixaban) or thrombin (inhibited by dabigatran) (7, 8, 14, 15) . In addition to the abovementioned antithrombotic mechanism of NOACs, heparins have other antithrombotic mechanisms, such as inhibiting interaction with mucin and cell adhesion molecules, activating heparin cofactor II and protein C, releasing tissue factor pathway inhibitor from the vascular epithelium, and neutralizing a wide variety of cytokines and chemokines (12) . Thus, heparins might have a stronger anticoagulation effect than warfarin and NOACs. Patients with more potent thrombi formation might require stronger anticoagulation treatment. In the present case, the tumor shrinkage achieved using chemotherapy might have weakened the thrombus formation activity and allowed the edoxaban to work well.
In addition to the tumor activity, a thrombotic state might influence the effects of anticoagulants. In the present case, when edoxaban was tried for the second time, the thrombus size regressed and the D-dimer level decreased. It is possible that the unstable parts of the thrombi were been dissolved with UFH and that only the stable parts remained.
Further studies are needed to detect the clinical factors and biomarkers that indicate thrombus formation activity; this will allow the selection of the appropriate anticoagulation treatment depending on the potency of thrombus formation. The site of the tumor, body mass index, hemoglobin level, thrombocyte count, and leukocyte count are associated with a risk of VTE in cancer patients (16). Furthermore, the TF level may predict not only the initial but also recurrent VTE (11, 17) . These factors might be indicators of thrombus formation as well as tumor size.
Conclusion
We showed for the first time that tumor size and activity might affect the outcome of anticoagulation therapy. After tumor shrinkage, NOACs may be effective and important treatment options for patients with both cancer and VTE; they have good efficacy and the ease of monitoring have the potential to improve the QOL of patients. Further studies are needed to determine the requirements for using NOACs as initial or long-term prophylactic therapy for VTE in cancer patients.
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